↓ Skip to main content

Dove Medical Press

Article Metrics

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies

Overview of attention for article published in Drug Design, Development and Therapy, April 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
27 Mendeley
Title
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
Published in
Drug Design, Development and Therapy, April 2015
DOI 10.2147/dddt.s83592
Pubmed ID
Authors

Qing-long Guo, Runzhe Chen, Fei Wang, Hongming Zhang

Abstract

Recently, brentuximab vedotin has become a promising therapeutic approach for CD30-positive hematological malignancies, but its role in other relapsed or refractory malignant lymphoma needs to be proven. Brentuximab vedotin was demonstrated effective, but no study has summarized the concrete effect of brentuximab vedotin in malignant lymphoma. To truly know the role of brentuximab vedotin, we performed a systematic review of the literature and a meta-analysis of all known prospective trials, to assess the value of brentuximab vedotin for patients with relapsed and refractory malignant lymphoma. This was a systematic review of publications indexed in the PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and ISI Web of Knowledge performed on February 10, 2015. Six studies, including 302 patients were identified. Meta-analyses were carried out to calculate the objective response rate (ORR), complete response rate (CRR), and partial response rate (PRR) of brentuximab vedotin for malignant lymphoma. In patients with malignant lymphoma, ORR was 0.61, CRR was 0.38, and PRR was 0.51. High heterogeneity between studies was observed, and funnel plots were not symmetrical, which means that publication bias existed. Brentuximab vedotin was generally well-tolerated by patients reported in the included studies; adverse effects also occurred, but they were considered manageable. Our analysis revealed a promising benefit of brentuximab vedotin in the treatment of relapsed and refractory malignant lymphoma. Larger sample of randomized controlled clinical trials are needed in the future.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 19%
Researcher 5 19%
Student > Master 4 15%
Student > Ph. D. Student 3 11%
Student > Doctoral Student 2 7%
Other 5 19%
Unknown 3 11%
Readers by discipline Count As %
Medicine and Dentistry 17 63%
Agricultural and Biological Sciences 2 7%
Social Sciences 2 7%
Immunology and Microbiology 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 1 4%
Unknown 3 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 May 2015.
All research outputs
#4,215,738
of 5,067,587 outputs
Outputs from Drug Design, Development and Therapy
#516
of 751 outputs
Outputs of similar age
#139,637
of 169,293 outputs
Outputs of similar age from Drug Design, Development and Therapy
#48
of 75 outputs
Altmetric has tracked 5,067,587 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 751 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,293 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.